Shares of Genzyme were buoyed slightly by the news that Mozobil hit primary and secondary goals in a late-stage trial for non-Hodgkin's lymphoma. The drug spurs the release of bone marrow stem cells into the blood so that they can be collected and used in a transplant. About six in 10 of the patients in the study demonstrated an increased stem cell count while 87 percent produced the necessary number of stem cells needed for a transplant. Applications for U.S. and European marketing approval is now expected in the first half of next year. Genzyme gained Mozobil when it bought out AnorMED earlier this year.
- read the release for more
- here's the AP report on the trial data